Beyond its antiangiogenic activity, regorafenib is able to reduce tumor-associated macrophages (TAMs) through the inhibition of the colony-stimulating factor 1 (CSF1) receptor, as demonstrated in tumor models [105]. This evidence concerns the gene CSF1 and neoplasm.